Evidence map›Paper›PMID 25217208›Full record

Observational studyJournal of general internal medicine2014

Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results.

Judith A Turner, Kathleen Saunders, Susan M Shortreed, Linda LeResche, Kim Riddell, Suzanne E Rapp, Michael Von Korff

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of general internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Prescribing controlled substances in sleep medicine clinics: an overview of legal issues and best safety practices.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Trends in Urine Drug Testing Among Long-term Opioid Users, 2012-2018.American journal of preventive medicine · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The utility of universal urinary drug screening in chronic pain management.Canadian journal of pain = Revue canadienne de la douleur · 2018
    Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Judith A TurnerDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA, jturner@uw.edu.
Kathleen Saunders
Susan M Shortreed
Linda LeResche
Kim Riddell
Suzanne E Rapp
Michael Von Korff
Kaiser Permanente Washington Health Research Institute · USUniversity of Washington · USGroup Health Cooperative · US

Funding

Transition to Long-Term Opioid Use Among Older Adults with Chronic PainR01AG034181 · NIA · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI VON KORFF, MICHAEL R · 2010 to 2014
$2.8M
NIA NIH HHS 1R01 AG034181NIA NIH HHS R01 AG034181
6 · The paper itself

Abstract

backgroundUrine drug tests (UDTs) are recommended for patients on chronic opioid therapy (COT). Knowledge of the risk factors for aberrant UDT results could help optimize their use.

objectiveTo identify primary care COT patient and opioid regimen characteristics associated with aberrant UDT results.

designPopulation-based observational. SAMPLE: 5,420 UDTs for Group Health integrated group practice COT patients. MEASURES: Group Health database measures of patient demographics, medical history, COT characteristics, and UDT results.

resultsThirty percent of UDTs had aberrant results, including prescribed opioid non-detection (12.3%), tetrahydrocannabinol (THC; 11.2%), non-prescribed opioid (5.3%), illicit drug (excluding THC; 0.6%), non-prescribed benzodiazepine (1.7%), and dilute (4.8%). Adjusted odds ratios (95% CI) of any aberrant result were higher for males than females (1.24 [1.07, 1.43]), patients with versus without prior substance use disorder diagnoses (1.42 [1.17, 1.72]), and current smokers versus non-smokers (1.50 [1.30, 1.73]). Odds ratios were lower for patients aged 45-64 (0.77 [0.65, 0.92]) and 65+ (0.40 [0.32, 0.50]) versus patients aged 20-44 and for patients on long-acting opioids only (0.72 [0.55, 0.95]) or long-acting plus short-acting (0.67 [0.54, 0.83]) versus short-acting only. Adjusted odds of prescribed opioid non-detection were lower for patients aged 45-64 (0.79 [0.63, 0.998]) and 65+ (0.44 [0.32, 0.59]) versus patients aged 20-44, for those on 40-<120 mg daily morphine-equivalent dose (0.52 [0.39, 0.70]) or 120+ mg (0.22 [0.11, 0.43]) versus <40 mg, and for patients on long-acting (0.35 [0.21, 0.57]) or long-acting plus short-acting (0.35 [0.24, 0.50]) opioids (versus short-acting only); and odds ratios were higher for patients with versus without prior diagnoses of substance use disorder (1.70 [1.31, 2.20]).

conclusionsIn this primary care setting, results were aberrant for 30% of UDTs of COT patients, largely because of prescribed opioid non-detection and THC. Aberrant results of almost all types were more likely among patients under the age of 45. Other risk factors varied across aberrancies, but commonly included current smoking and prior substance use disorder diagnosis.

Indexed as

AdultAgedAnalgesics, OpioidChronic PainDrug Administration ScheduleDrug MonitoringFemaleHumansMaleMiddle AgedOpioid-Related DisordersPractice Guidelines as TopicPrimary Health CareSubstance Abuse DetectionWashingtonYoung AdultAnalgesics, Opioid

Identifiers

PMID25217208
PMCPMC4242878
OpenAlexW2127280141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.